6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2008

Commission File Number: 001-31995

MEDICURE INC.
(Translation of registrant's name into English)

4-1200 Waverley Street
Winnipeg, MB Canada R3T 0P4
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[ x ] Form 20-F   [] Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): []

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): []

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [] No [ x ]

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _________

SUBMITTED HEREWITH

Exhibits

99.1	News Release dated June 18, 2008
99.2	Material Change Report dated June 11, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Medicure Inc.
	(Registrant)
Date: June 18, 2008	By:	/s/ Dr. Albert D. Friesen
		Dr. Albert D. Friesen
	Title:	President & CEO

EX-99.1

	4-1200 Waverley Street
	Winnipeg, Manitoba,
	Canada R3T 0P4
	Phone: 204 487 7412
	Fax: 204-488-9823

MEDICURE ANNOUNCES INTENTION TO DELIST FROM THE AMERICAN STOCK EXCHANGE

WINNIPEG, Manitoba – (June 18, 2008) Medicure Inc. (TSX:MPH; Amex:MCU) today announced that its Board of Directors has unanimously decided to submit a written notice to the American Stock Exchange ("Amex") of its intention to file a Form 25 with the United States Securities and Exchange Commission in order to voluntarily delist its common shares ("Shares") from Amex.

Medicure previously announced that it received a letter from Amex stating that Amex has determined that Medicure is not in compliance with certain continued listing standards, as set forth in Part 10 of the Amex Company Guide (the "Company Guide"), and that failure to regain compliance with Amex's listing requirements by November 24, 2008, would result in Amex initiating delisting proceedings pursuant to Section 1009 of the Company Guide. After further consideration in light of the Company’s business needs, Medicure has decided to voluntarily delist its Shares from Amex. It is expected that listing of the Shares on Amex will cease on or about July 7, 2008.

The Shares will continue to be traded on the Toronto Stock Exchange (the “TSX”). Medicure's Board of Directors unanimously approved the delisting and deregistration of the Shares, noting that the TSX is the more significant trading market for the Shares. Medicure does not believe that its shareholders in the United States will be materially prejudiced by a voluntary delisting from Amex since its U.S. shareholders will continue to be able to trade the Shares through the facilities of the TSX.

About Medicure Inc.
Medicure Inc is a biopharmaceutical company focused on the research, development and commercialization of novel compounds to treat cardiovascular disorders. Cardiovascular medicine represents the largest pharmaceutical sector, with annual global sales of over US $70 billion. Medicure aims to make a global impact on cardiovascular disease and stroke by reducing deaths, improving the quality of life and serving the unmet needs of people who suffer from cardiovascular disease and stroke.

This press release contains forward-looking statements, as defined under applicable securities legislation, that involve risks, which may cause actual results to differ materially from the statements made, and accordingly may be deemed to be forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise except as required by law. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the Company’s stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market the Company’s products, the ability to protect its intellectual property, dependence on collaborative partners and the ability to meet its debt obligations. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Additional risks and uncertainties relating to the Company and its business can be found in the “Risk Factors” section of its Form 20F for the year ended May 31, 2007 and the Company’s MD&A for the third quarter ended February 29, 2008.

For more information, please contact:
Albert D. Friesen
President & CEO
Tel. 888-435-2220
Fax 204-488-9823
E-mail: info@medicure.com
Web: www.medicure.com

EX-99.2

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1	Name and Address of Company
	Medicure Inc.
	4 - 1200 Waverley Street Winnipeg, Manitoba R3T 0P4
Item 2	Date of Material Change
	June 11, 2008
Item 3	News Release
	A press release with respect to the material change described herein was issued via Marketwire and filed on SEDAR on June 11, 2008.
Item 4	Summary of Material Change
	On June 11, 2008, Medicure Inc. (TSX:MPH) (AMEX:MCU) (“Medicure” or the “Company”), a cardiovascular focused, biopharmaceutical company, announced the appointment of Dwayne Henley as its new Chief Financial Officer. Mr. Henley is a Chartered Accountant with nearly 10 years of senior management and finance experience in both public and private companies. Mr. Henley will replace, Derek Reimer, who has resigned to pursue other interests.
Item 5	Full Description of Material Change
	On June 11, 2008, Medicure announced the appointment of Dwayne Henley as its new Chief Financial Officer. Mr. Henley is a Chartered Accountant with nearly 10 years of senior management and finance experience in both public and private companies. Mr. Henley will replace, Derek Reimer, who has resigned to pursue other interests.
	Mr. Henley joined Medicure from a private investment and management company where he held the position of Vice President of Finance. Prior to that Mr. Henley was Vice-President Finance for a privately owned transportation company operating throughout North America. Other notable experience includes Assante Corporation where he held the position of Corporate Controller and Biovail Laboratories Inc. where he held the position of Manager, Finance and Administration.
Item 6	Reliance on subsection 7.1(2) or (3) of National Instrument 51-102
	Confidentiality is not requested.
Item 7	Omitted Information
	Not applicable.

- 2 -

Item 8 Executive Officer For further information contact Albert D. Friesen, President & Chief Executive Officer of Medicure Inc. at the above-mentioned address or by telephone at 1-888-435-2220.

The foregoing accurately discloses the material change referred to herein.

DATED at Winnipeg, Manitoba, this 12th day of June, 2008.

MEDICURE INC.
By:	/ s/ Albert D. Friesen
	Name: Albert D. Friesen
	Title: President